Biomedical engineers have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.
Click here for original story, New pharmaceutical target reverses osteoporosis in mice
Source: ScienceDaily